

Na⁺/H⁺ Exchangers

Molecular Diversity and Relevance to Heart

JOHN ORLOWSKI^a

Department of Physiology, McGill University, Montreal, H3G 1Y6, Canada

ABSTRACT: During the last several years, significant advances have been made in our understanding of the molecular, cellular, and physiological diversity of mammalian Na⁺/H⁺ exchangers. This transporter forms a multigene family of at least six members (NHE1–NHE6) that share ~20–60% amino acid identity. NHE1 is the most predominant isoform expressed in heart and it contributes significantly to myocardial pH_i homeostasis, which is important for maintaining contractility. However, hyperactivation of NHE1 during episodes of cardiac ischemia and reperfusion disrupts the intracellular ion balance, leading to cardiac dysfunction and damage in several animal models, but which can be prevented by pharmacological antagonists of NHE1. Molecular studies have indicated that the predicted transmembrane segments M4 and M9 contain several residues involved in drug sensitivity. Molecular dissection of the drug binding region should facilitate the rational design of more potent and isoform-specific drugs that may provide therapeutic benefit in the prevention of cardiac ischemia and reperfusion injuries.

ROLES OF THE Na⁺/H⁺ EXCHANGER IN CARDIAC PHYSIOLOGY AND PATHOPHYSIOLOGY

Myocardial function is greatly influenced by changes in intracellular pH (pH_i). For example, myocardial acidosis results in marked decreases in contractility,¹ which is associated with reduced myosin-ATPase activity,² diminished binding of Ca²⁺ to troponin C of the contractile apparatus,³ decreased ion currents through voltage-activated Na⁺ and Ca²⁺ channels,^{4–6} and reductions in gap junction conductance.⁷ Hence, regulation of pH_i is of critical importance for maintaining cardiac function.

At least three different ion transporters contribute to myocardial pH_i regulation; the Cl[−]/HCO₃[−] exchanger,^{8,9} the Na⁺-HCO₃[−] cotransporter,^{10,11} and the Na⁺/H⁺ exchanger.^{12–14} An increase in pH_i activates the Cl[−]/HCO₃[−] exchanger, which extrudes intracellular HCO₃[−] for extracellular Cl[−]. By contrast, intracellular acidification activates both the Na⁺-HCO₃[−] cotransporter and the Na⁺/H⁺ exchanger, with the latter being the predominant mechanism for restoring myocardial pH_i to the neutral range (pH_i 7.1 to 7.3).^{10,11,13}

Aside from its role in normal myocardial pH_i homeostasis, accumulating evidence points to the Na⁺/H⁺ exchanger as a contributing factor in the pathophysiology of cardiac ischemia and reperfusion injuries. During cardiac ischemia, ATP stores

^aAddress correspondence to: Dr. John Orłowski, Department of Physiology, McGill University, McIntyre Medical Science Bldg., 3655 Drummond St., Montreal, Quebec H3G 1Y6 Canada; Telephone: (514) 398-8335; Fax: (514) 398-7452; E-mail: orlowski@physio.mcgill.ca

are depleted as a consequence of depressed mitochondrial activity and lactic acid levels are increased due to anaerobic metabolism of glucose. This results in a rapid decrease in both intracellular and extracellular pH, which precipitates a series of other changes in myocardial ion homeostasis, primarily Na^+_i and Ca^{2+}_i overloads, which then lead to cardiac dysfunction and tissue damage (for further details^{15–19}). Ischemia elevates Na^+_i by two mechanisms: the acidosis that occurs during the first few minutes of ischemia leads to an influx of Na^+ by activation of the Na^+/H^+ exchanger, and the diminished ATP levels cause depression of Na^+/K^+ -ATPase activity, which normally extrudes Na^+_i . Indeed, the Na^+/H^+ exchanger accounts for as much as 50% of the cardiac membrane's basal permeability to Na^+ following intracellular acidification.^{20–22} Furthermore, the reduction in ATP levels also causes a decrease in the pH_i sensitivity (or threshold for activation) of the Na^+/H^+ exchanger, thereby impairing its ability to fully restore pH_i to neutral.²³ The net result is a chronic state of cellular acidosis.

The elevation of Na^+_i reduces the transmembrane Na^+ gradient, thereby inhibiting $\text{Na}^+/\text{Ca}^{2+}$ exchangers that, under normal conditions, extrude Ca^{2+}_i in exchange for Na^+_o . Moreover, if Na^+_i increases sufficiently the $\text{Na}^+/\text{Ca}^{2+}$ exchanger could reverse and mediate Ca^{2+} influx. This Ca^{2+}_i overload is associated with cardiac arrhythmias and, if untreated, contributes to contractile failure. Reperfusion of the failing heart with physiological fluids to restore pH_i is the standard approach to rescuing the tissue, but may lead to further tissue damage. This has been referred to as the “pH paradox.” Rapid removal of the acidic extracellular fluid generates a large transmembrane pH gradient that drives Na^+/H^+ exchange. This further augments Na^+_i and markedly elevates Ca^{2+}_i , causing reperfusion arrhythmias, contractile failure, and cellular necrosis. Thus, the Na^+/H^+ exchanger appears to play a central role in injuries caused by ischemia and reperfusion.

The involvement of Na^+/H^+ exchangers in ischemia- and reperfusion-induced injuries, however, is most convincingly demonstrated by animal studies showing that treatment with amiloride, a relatively weak inhibitor of the Na^+/H^+ exchanger, significantly reduces Na^+ and Ca^{2+} overload and is cardioprotective.²⁴ Similar protective effects are obtained with amiloride analogues,^{25–33} and benzoyl guanidinium compounds such as HOE694,^{34–38} HOE642 (cariporide),^{39–43} and compound 246,⁴⁴ which are more potent and selective antagonists of the Na^+/H^+ exchanger. The beneficial effects of these compounds are obtained only during the early stages (within several minutes) of ischemia and reperfusion when the Na^+/H^+ exchanger is most active. The antiarrhythmic action of amiloride has also been demonstrated in human clinical studies, where it suppressed inducible ventricular tachycardia⁴⁵ and spontaneous ventricular premature beats.⁴⁶ Thus, these observations strongly implicate overactivation of the Na^+/H^+ exchanger as a central factor in ischemia- and reperfusion-induced injuries.

EXPRESSION AND LOCALIZATION OF Na^+/H^+ EXCHANGER ISOFORMS IN HEART

In mammals, at least six Na^+/H^+ exchanger isoforms (NHE1 to NHE6) are known to exist and they exhibit distinct differences in their primary structures (~20–60%

amino acid identity), patterns of tissue expression, membrane localization, functional properties, and physiological roles.^{47,48}

Mammalian cardiac tissue expresses predominantly the NHE1 mRNA,^{49–52} albeit minor amounts of NHE2 mRNA are also detected in some species.⁵⁰ Indeed, NHE1 is present in virtually all tissues and most cell types examined, consistent with its proposed “housekeeping” role to maintain intracellular pH and cell volume.^{49,53,54} Thus, the functional characteristics of the cardiac sarcolemmal Na^+/H^+ exchanger described in numerous studies are most likely those of NHE1.

Recent immunological studies have demonstrated that NHE1 is localized predominantly at the intercalated disc regions and to a lesser extent along the transverse tubular systems of both atrial and ventricular muscle cells.⁸¹ Unexpectedly, NHE1 was not detected along the lateral sarcolemmal membranes. This distribution differs somewhat from the $\text{Cl}^-/\text{HCO}_3^-$ exchangers which accumulate mainly at the lateral sarcolemma and transverse tubules of isolated adult rat ventricular myocytes.⁵⁵ The location of the other major cardiac pH regulatory protein, the $\text{Na}^+/\text{HCO}_3^-$ cotransporter, is currently unknown. The physiological relevance of the high density of NHE1 at the intercalated discs is unclear. While speculative, in this region it may serve to regulate the opening of gap junction channels, which are highly sensitive to minor fluctuations in pH_i within the physiological range,^{7,56} and thereby to influence impulse conduction between myocytes.

The heart also expresses NHE6, but it is localized to the mitochondria inner membrane⁵⁷ where it is responsible for extruding Na^+ from the alkaline matrix of respiring mitochondria⁵⁸ and, as such, may contribute to organellar volume homeostasis.⁵⁹ This process may also be functionally coupled to the efflux of Ca^{2+} from the mitochondria by the recycling of Na^+ between the mitochondrial Na^+/H^+ and $\text{Na}^+/\text{Ca}^{2+}$ exchangers.^{59,60} There are indications that the mitochondrial NHE is also responsible for mediating transport of NH_4^+ from the mitochondrial matrix.⁶¹

STRUCTURAL AND FUNCTIONAL FEATURES OF THE Na^+/H^+ EXCHANGER

The NHE isoforms exhibit similar membrane topologies, with 12 predicted membrane-spanning (M) regions at the N-terminus and a large cytoplasmic region at the C-terminus. The most highly conserved regions of the NHE isoforms are the membrane-spanning segments, which probably mediate cation transport and drug binding. The C-terminal regions are highly hydrophilic and exhibit a lower degree of similarity among isoforms. Structural studies indicate that this latter region is involved in regulation by growth factors and other mitogens, consistent with it being oriented towards the cytoplasmic side of the membrane.^{47,48}

Even less is known about the tertiary or quaternary structure of Na^+/H^+ exchangers, although recent evidence suggests that they exist in the membrane as homodimers.^{62,63} The site of interaction between the monomers resides in the putative transmembranous region,⁶³ possibly linked by disulfide bonding,⁶² although the precise location(s) of contact have yet to be defined.

As mentioned above, the NHE is a known target for inhibition by the diuretic compound amiloride and its analogues.⁶⁴ Amiloride analogues containing hydro-

phobic substituents on the 5-amino group of the pyrazine ring have higher affinity and specificity for the NHE relative to other ion transporters. Using a heterologous expression system, NHE isoforms exhibit a wide range of affinities for amiloride and its analogues, which span over two orders of magnitude and show the following order of sensitivity: $\text{NHE1} \geq \text{NHE2} \gg \text{NHE3}$.^{65,66} Recently, HOE694^{67,68} and its related compound HOE642³⁹ have also been found to inhibit the isoforms with a similar rank order as the amiloride compounds, but over a larger concentration range (three to four orders of magnitude). Other pharmacological agents, such as cimetidine, clonidine, and harmaline, also exhibit differential affinities for the NHE isoforms.^{65,66} While these compounds are chemically unrelated to amiloride or HOE694, they possess either an imidazoline or guanidinium moiety and hence bear some structural similarity to these compounds.

Biochemical analyses indicate that inhibition by amiloride compounds, cimetidine,⁷³ and HOE694⁶⁷ is reduced by high external Na^+ . This competitive inhibition suggests they bind near the external Na^+ transport site and may also share a common site. However, under different anionic buffer conditions, amiloride and its derivatives also inhibit transport noncompetitively, suggesting that the external Na^+ - and amiloride-binding sites may not be identical.^{74,75} Furthermore, the extracellular Na^+ - and amiloride-binding sites can be altered independently of each other using genetic selection techniques.⁷⁶ Taken together, these data indicate that amiloride and other antagonists probably interact with multiple sites on the exchanger.

Consistent with this idea, recent molecular studies of human NHE1 have shown that two predicted membrane-associated domains are targets for interaction with amiloride and its analogues. Residues in the fourth (Phe¹⁶¹, Leu¹⁶³, Gly¹⁷⁴)^{77,78} and the ninth (His³⁴⁹)⁷⁹ transmembrane segments appear to contribute to amiloride sensitivity without affecting Na^+ affinity. Likewise, mutagenesis of a homologous residue in the fourth transmembrane domain of rabbit NHE2 (Leu¹⁴³ \rightarrow Phe¹⁴³) also reduced its sensitivity to amiloride compounds.⁸⁰ However, mutations at each of these sites produced only modest changes in drug sensitivity and did not confer the degree of drug resistance observed for the NHE3 isoform.^{65,67,77} Thus, other residues of the exchanger are presumably involved in determining drug sensitivity.

A recent analysis of chimeric NHE1 and NHE3 proteins identified a 66 amino acid segment containing the putative ninth transmembrane (M9) domain and its adjacent loops that significantly influences drug sensitivity.⁶⁸ Homologous substitution of this region between isoforms caused a reciprocal change in the drug sensitivities of NHE1 and NHE3 by one to three orders of magnitude, depending on the drug. The greatest changes in affinity were for ethylisopropylamiloride and HOE694. These alterations differ from those caused by mutations at His³⁴⁹ in the putative M9 domain of human NHE1, where either a modest twofold increase (His³⁴⁹ \rightarrow Tyr or Phe) or twofold decrease (His³⁴⁹ \rightarrow Gly or Leu) in amiloride sensitivity was observed, whereas other amino acid substitutions at this position had no effect.⁷⁹ This suggests that other residues within this region serve as major determinants in conferring drug sensitivity. Further molecular dissection of the drug binding region could be helpful in developing more potent and isoform-specific drugs that may be of therapeutic benefit in the prevention of cardiac ischemia and reperfusion injuries.

REFERENCES

1. ORCHARD, C.H. & J.C. KENTISH. 1990. Effects of changes of pH on the contractile function of cardiac muscle. *Am. J. Physiol.* **258**: C967–C981.
2. KENTISH, J.C. & W.G. NAYLER. 1979. The influence of pH on the Ca^{2+} -regulated ATPase of cardiac and white skeletal myofibrils. *J. Mol. Cell. Cardiol.* **11**: 611–617.
3. BLANCHARD, E.M. & R.J. SOLARO. 1984. Inhibition of the activation and troponin calcium binding of dog cardiac myofibrils by acidic pH. *Circ. Res.* **55**: 382–391.
4. ZHANG, J.F. & S.A. SIEGELBAUM. 1991. Effects of external protons on single cardiac sodium channels from guinea pig ventricular myocytes. *J. Gen. Physiol.* **98**: 1065–1083.
5. IRISAWA, H. & R. SATO. 1986. Intra- and extracellular actions of proton on the calcium current of isolated guinea pig ventricular cells. *Circ. Res.* **59**: 348–355.
6. SATO, R., A. NOMA, Y. KURACHI & H. IRISAWA. 1985. Effects of intracellular acidification on membrane currents in ventricular cells of the guinea pig. *Circ. Res.* **57**: 553–561.
7. SPRAY, D.C., R.L. WHITE, F. MAZET & M.V. BENNETT. 1985. Regulation of gap junctional conductance. [Review]. *Am. J. Physiol.* **248**: H753–H764.
8. VAUGHAN-JONES, R.D. 1979. Regulation of chloride in quiescent sheep-heart Purkinje fibres studied using intracellular chloride and pH-sensitive micro-electrodes. *J. Physiol. (Lond.)* **295**: 111–137.
9. LIU, S., D. PIWNICA-WORMS & M. LIEBERMAN. 1990. Intracellular pH regulation in cultured embryonic chick heart cells. Na^+ -dependent $\text{Cl}^-/\text{HCO}_3^-$ exchange. *J. Gen. Physiol.* **96**: 1247–1269.
10. LAGADIC-GOSSMANN, D., K.J. BUCKLER & R.D. VAUGHAN-JONES. 1992. Role of bicarbonate in pH recovery from intracellular acidosis in the guinea-pig ventricular myocyte. *J. Physiol. (Lond.)* **458**: 361–384.
11. DART, C. & R.D. VAUGHAN-JONES. 1992. Na^+ - HCO_3^- symport in the sheep cardiac Purkinje fibre. *J. Physiol. (Lond.)* **451**: 365–385.
12. PIWNICA-WORMS, D. & M. LIEBERMAN. 1983. Microfluorometric monitoring of pH_i in cultured heart cells: Na^+ - H^+ exchange. *Am. J. Physiol.* **244**: C422–C428.
13. LAZDUNSKI, M., C. FRELIN & P. VIGNE. 1985. The sodium/hydrogen exchange system in cardiac cells: its biochemical and pharmacological properties and its role in regulating internal concentrations of sodium and internal pH. *J. Mol. Cell. Cardiol.* **17**: 1029–1042.
14. WALLERT, M.A. & O. FRÖHLICH. 1989. Na^+ - H^+ exchange in isolated myocytes from adult rat heart. *Am. J. Physiol.* **257**: C207–C213.
15. KARMAZYN, M. & M.P. MOFFAT. 1993. Role of Na^+/H^+ exchange in cardiac physiology and pathophysiology: Mediation of myocardial reperfusion injury by the pH paradox. *Cardiovasc. Res.* **27**: 915–924.
16. SCHOLZ, W. & U. ALBUS. 1993. Na^+/H^+ exchange and its inhibition in cardiac ischemia and reperfusion. *Basic Res. Cardiol.* **88**: 443–455.
17. PIERCE, G.N. & H. MENG. 1992. The role of sodium-proton exchange in ischemic/reperfusion injury in the heart. *Am. J. Cardiovasc. Pathol.* **4**: 91–102.
18. FLIEGEL, L. & J.R.B. DYCK. 1995. Molecular biology of the cardiac sodium/hydrogen exchanger. *Cardiovasc. Res.* **29**: 155–159.
19. DUFF, H.J. 1995. Clinical and *in vivo* antiarrhythmic potential of sodium-hydrogen exchange inhibitors. *Cardiovasc. Res.* **29**: 189–193.
20. FRELIN, C., P. VIGNE & M. LAZDUNSKI. 1984. The role of the Na^+/H^+ exchange system in cardiac cells in relation to the control of the internal Na^+ concentration. A molecular basis for the antagonistic effect of ouabain and amiloride on the heart. *J. Biol. Chem.* **259**: 8880–8885.
21. KIM, D. & T.W. SMITH. 1986. Effects of amiloride and ouabain on contractile state, Ca and Na fluxes, and Na content in cultured chick heart cells. *Mol. Pharmacol.* **29**: 363–371.
22. TANI, M. & J.R. NEELY. 1991. Deleterious effects of digitalis on reperfusion-induced arrhythmias and myocardial injury in ischemic rat hearts: possible involvements of myocardial Na^+ and Ca^{2+} imbalance. *Basic Res. Cardiol.* **86**: 340–354.

23. WEISSBERG, P.L., P.J. LITTLE, E.J. CRAGOE, JR. & A. BOBIK. 1989. The pH of spontaneously beating cultured rat heart cells is regulated by an ATP-calmodulin-dependent Na^+/H^+ antiport. *Circ. Res.* **64**: 676–685.
24. KARMAZYN, M. 1988. Amiloride enhances postischemic ventricular recovery: possible role of Na^+/H^+ exchange. *Am. J. Physiol.* **255**: H608–H615.
25. KARMAZYN, M., M. RAY & J.V. HAIST. 1993. Comparative effects of Na^+/H^+ exchange inhibitors against cardiac injury produced by ischemia/reperfusion, hypoxia/reoxygenation, and the calcium paradox. *J. Cardiovasc. Pharmacol.* **21**: 172–178.
26. MOFFAT, M.P. & M. KARMAZYN. 1993. Protective effects of the potent Na/H exchange inhibitor methylisobutyl amiloride against post-ischemic contractile dysfunction in rat and guinea-pig hearts. *J. Mol. Cell. Cardiol.* **25**: 959–971.
27. MENG, H.P. & G.N. PIERCE. 1990. Protective effects of 5-(*N,N*-dimethyl)amiloride on ischemia-reperfusion injury in hearts. *Am. J. Physiol.* **258**: H1615–H1619.
28. MENG, H.-P., T.G. MADDAFORD & G.N. PIERCE. 1993. Effect of amiloride and selected analogues on postischemic recovery of cardiac contractile function. *Am. J. Physiol.* **264**: H1831–H1835.
29. DUFF, H.J., C.E. BROWN, E.J. CRAGOE, JR. & M. RAHMBERG. 1991. Antiarrhythmic activity of amiloride: mechanisms. *J. Cardiovasc. Pharmacol.* **17**: 879–888.
30. MYERS, M.L., S. MATHUR, G.-H. LI & M. KARMAZYN. 1995. Sodium-hydrogen exchange inhibitors improve postischemic recovery of function in the perfused rabbit heart. *Cardiovasc. Res.* **29**: 209–214.
31. KAPLAN, S.H., H. YANG, D.E. GILLIAM, J. SHEN, J.J. LEMASTERS & W.E. CASCIO. 1995. Hypercapnic acidosis and dimethyl amiloride reduce reperfusion induced cell death in ischaemic ventricular myocardium. *Cardiovasc. Res.* **29**: 231–238.
32. TANI, M., K. SHINMURA, H. HASEGAWA & Y. NAKAMURA. 1996. Effect of methylisobutyl amiloride on $[\text{Na}^+]_i$, reperfusion arrhythmias, and function in ischemic rat hearts. *J. Cardiovasc. Pharmacol.* **27**: 794–801.
33. PIERCE, G.N., W.C. COLE, K. LIU, H. MASSAELI, T.G. MADDAFORD, Y.J. CHEN, C.D. MCPHERSON, S. JAIN & D. SONTAG. 1993. Modulation of cardiac performance by amiloride and several selected derivatives of amiloride. *J. Pharmacol. Exp. Ther.* **265**: 1280–1291.
34. SCHOLZ, W., U. ALBUS, H.J. LANG, W. LINZ, P.A. MARTORANA, H.C. ENGLERT & B.A. SCHÖLKENS. 1993. HOE 694, a new Na^+/H^+ exchange inhibitor and its effects in cardiac ischaemia. *Br. J. Pharmacol.* **109**: 562–568.
35. HENDRIKX, M., K. MUBAGWA, F. VERDONCK, K. OVERLOOP, P. VAN HECKE, F. VAN-STAPEL, A. VAN LOMMEL, E. VERBEKEN, J. LAUWERYS & W. FLAMENG. 1994. New Na^+/H^+ exchange inhibitor HOE 694 improves postischemic function and high-energy phosphate resynthesis and reduces Ca^{2+} overload in isolated perfused rabbit heart. *Circulation* **89**: 2787–2798.
36. HARPER, I.S., J.M. BOND, E. CHACON, J.M. REECE, B. HERMAN & J.J. LEMASTERS. 1993. Inhibition of Na^+/H^+ exchange preserves viability, restores mechanical function, and prevents the pH paradox in reperfusion injury to rat neonatal myocytes. *Basic Res. Cardiol.* **88**: 430–442.
37. YASUTAKE, M., C. IBUKI, D.J. HEARSE & M. AVKIRAN. 1994. Na^+/H^+ exchange and reperfusion arrhythmias: Protection by intracoronary infusion of a novel inhibitor. *Am. J. Physiol.* **267**: H2430–H2440.
38. MYERS, M.L. & M. KARMAZYN. 1996. Improved cardiac function after prolonged hypothermic ischemia with the Na^+/H^+ exchange inhibitor HOE 694. *Ann. Thorac. Surg.* **61**: 1400–1406.
39. SCHOLZ, W., U. ALBUS, L. COUNILLON, H. GÖGELEIN, H.-J. LANG, W. LINZ, A. WEICHERT & B.A. SCHÖLKENS. 1995. Protective effects of HOE642, a selective sodium-hydrogen exchange subtype 1 inhibitor, on cardiac ischaemia and reperfusion. *Cardiovasc. Res.* **29**: 260–268.
40. XUE, Y.X., N.N. AYE & K. HASHIMOTO. 1996. Antiarrhythmic effects of HOE642, a novel Na^+/H^+ exchange inhibitor, on ventricular arrhythmias in animal hearts. *Eur. J. Pharmacol.* **317**: 309–316.

41. AYE, N.N., Y.X. XUE & K. HASHIMOTO. 1997. Antiarrhythmic effects of cariporide, a novel $\text{Na}^+\text{-H}^+$ exchange inhibitor, on reperfusion ventricular arrhythmias in rat hearts. *Eur. J. Pharmacol.* **339**: 121–127.
42. SHIPOLINI, A.R., M. GALIÑANES, S.J. EDMONDSON, D.J. HEARSE & M. AVKIRAN. 1997. $\text{Na}^+\text{/H}^+$ exchanger inhibitor HOE-642 improves cardioplegic myocardial preservation under both normothermic and hypothermic conditions. *Circulation* **96**: 266–273.
43. CHAKRABARTI, S., A.N. HOQUE & M. KARMAZYN. 1997. A rapid ischemia-induced apoptosis in isolated rat hearts and its attenuation by the sodium-hydrogen exchange inhibitor HOE 642 (Cariporide). *J. Mol. Cell. Cardiol.* **29**: 3169–3174.
44. BAUMGARTH, M., N. BEIER & R. GERICKE. 1997. (2-methyl-5-(methylsulfonyl)benzoyl) guanidine $\text{Na}^+\text{/H}^+$ antiporter inhibitors. *J. Med. Chem.* **40**: 2017–2034.
45. DUFF, H.J., L.B. MITCHELL, K.M. KAVANAGH, D.E. MANYARI, A.M. GILLIS & D.G. WYSE. 1989. Amiloride: antiarrhythmic and electrophysiological actions in patients with sustained ventricular tachycardia. *Circulation* **79**: 1257–1263.
46. MYERS, M. 1990. Diuretic therapy and ventricular arrhythmias in persons 65 years of age and older. *Am. J. Cardiol.* **65**: 599–603.
47. ORLOWSKI, J. & S. GRINSTEIN. 1997. $\text{Na}^+\text{/H}^+$ exchangers in mammalian cells. *J. Biol. Chem.* **272**: 22373–22376.
48. WAKABAYASHI, S., M. SHIGEKAWA & J. POUYSSÉGUR. 1997. Molecular physiology of vertebrate $\text{Na}^+\text{/H}^+$ exchangers. *Physiol. Rev.* **77**: 51–74.
49. ORLOWSKI, J., R.A. KANDASAMY & G.E. SHULL. 1992. Molecular cloning of putative members of the Na/H exchanger gene family. cDNA cloning, deduced amino acid sequence, and mRNA tissue expression of the rat Na/H exchanger NHE-1 and two structurally related proteins. *J. Biol. Chem.* **267**: 9331–9339.
50. WANG, Z., J. ORLOWSKI & G.E. SHULL. 1993. Primary structure and functional expression of a novel gastrointestinal isoform of the rat Na/H exchanger. *J. Biol. Chem.* **268**: 11925–11928.
51. TSE, C.-M., S. LEVINE, C. YUN, S. BRANT, L.T. COUNILLON, J. POUYSSÉGUR & M. DONOWITZ. 1993. Structure/function studies of the epithelial isoforms of the mammalian $\text{Na}^+\text{/H}^+$ exchanger gene family. *J. Membr. Biol.* **135**: 93–108.
52. FLIEGEL, L., J.R.B. DYCK, H. WANG, C. FONG & R.S. HAWORTH. 1993. Cloning and analysis of the human myocardial $\text{Na}^+\text{/H}^+$ exchanger. *Mol. Cell. Biochem.* **125**: 137–143.
53. TSE, C.-M., A.I. MA, V.W. YANG, A.J.M. WATSON, S. LEVINE, M.H. MONTROSE, J. POTTER, C. SARDET, J. POUYSSÉGUR & M. DONOWITZ. 1991. Molecular cloning and expression of a cDNA encoding the rabbit ileal villus cell basolateral membrane $\text{Na}^+\text{/H}^+$ exchanger. *EMBO J.* **10**: 1957–1967.
54. HILDEBRANDT, F., J.H. PIZZONIA, R.F. REILLY, N.A. REBOUÇAS, C. SARDET, J. POUYSSÉGUR, C.W. SLAYMAN, P.S. ARONSON & P. IGARASHI. 1991. Cloning, sequence, and tissue distribution of a rabbit renal $\text{Na}^+\text{/H}^+$ exchanger transcript. *Biochim. Biophys. Acta Gene Struct. Expression* **1129**: 105–108.
55. PUCÉAT, M., I. KORICHNEVA, R. CASSOLY & G. VASSORT. 1995. Identification of band 3-like proteins and $\text{Cl}^-/\text{HCO}_3^-$ exchange in isolated cardiomyocytes. *J. Biol. Chem.* **270**: 1315–1322.
56. WHITE, R.L., J.E. DOELLER, V.K. VERSELIS & B.A. WITTENBERG. 1990. Gap junctional conductance between pairs of ventricular myocytes is modulated synergistically by H^+ and Ca^{++} . *J. Gen. Physiol.* **95**: 1061–1075.
57. NUMATA, M., K. PETRECCA, N. LAKE & J. ORLOWSKI. 1998. Identification of a mitochondrial $\text{Na}^+\text{/H}^+$ exchanger. *J. Biol. Chem.* **273**: 6951–6959.
58. BRIERLEY, G.P., M.H. DAVIS, E.J. CRAGOE, JR. & D.W. JUNG. 1989. Kinetic properties of the $\text{Na}^+\text{/H}^+$ antiport of heart mitochondria. *Biochemistry* **28**: 4337–4354.
59. CROMPTON, M. & I. HEID. 1978. The cycling of calcium, sodium, and protons across the inner membrane of cardiac mitochondria. *Eur. J. Biochem.* **91**: 599–608.
60. CROMPTON, M., R. MOSER, H. LUNDI & E. CARAFOLI. 1978. The interrelations between the transport of sodium and calcium in mitochondria of various mammalian tissues. *Eur. J. Biochem.* **82**: 25–31.
61. SASTRASINH, M., P. YOUNG, E.J. CRAGOE, JR. & S. SASTRASINH. 1995. The $\text{Na}^+\text{/H}^+$ antiport in renal mitochondria. *Am. J. Physiol.* **268**: C1227–C1234.
62. FLIEGEL, L., R.S. HAWORTH & J.R.B. DYCK. 1993. Characterization of the placental

- brush border membrane Na^+/H^+ exchanger: Identification of thiol-dependent transitions in apparent molecular size. *Biochem. J.* **289**: 101–107.
63. FAFOURNOUX, P., J. NOËL & J. POUYSSÉGUR. 1994. Evidence that Na^+/H^+ exchanger isoforms NHE1 and NHE3 exist as stable dimers in membranes with a high degree of specificity for homodimers. *J. Biol. Chem.* **269**: 2589–2596.
 64. KLEYMAN, T.R. & E.J. CRAGOE, JR. 1988. Amiloride and its analogs as tools in the study of ion transport. *J. Membr. Biol.* **105**: 1–21.
 65. ORLOWSKI, J. 1993. Heterologous expression and functional properties of the amiloride high affinity (NHE-1) and low affinity (NHE-3) isoforms of the rat Na/H exchanger. *J. Biol. Chem.* **268**: 16369–16377.
 66. YU, F.H., G.E. SHULL & J. ORLOWSKI. 1993. Functional properties of the rat Na/H exchanger NHE-2 isoform expressed in Na/H exchanger-deficient Chinese hamster ovary cells. *J. Biol. Chem.* **268**: 25536–25541.
 67. COUNILLON, L., W. SCHOLZ, H.J. LANG & J. POUYSSÉGUR. 1993. Pharmacological characterization of stably transfected Na^+/H^+ antiporter isoforms using amiloride analogs and a new inhibitor exhibiting anti-ischemic properties. *Mol. Pharmacol.* **44**: 1041–1045.
 68. ORLOWSKI, J. & R.A. KANDASAMY. 1996. Delineation of transmembrane domains of the Na^+/H^+ exchanger that confer sensitivity to pharmacological antagonists. *J. Biol. Chem.* **271**: 19922–19927.
 69. KINSELLA, J.L. & P.S. ARONSON. 1981. Amiloride inhibition of the Na^+/H^+ exchanger in renal microvillus membrane vesicles. *Am. J. Physiol.* **241**: F374–F379.
 70. MAHNENSMITH, R.L. & P.S. ARONSON. 1985. Interrelationships among quinidine, amiloride, and lithium as inhibitors of the renal Na^+/H^+ exchanger. *J. Biol. Chem.* **260**: 12586–12592.
 71. PARIS, S. & J. POUYSSÉGUR. 1983. Biochemical characterization of the amiloride-sensitive Na^+/H^+ antiport in Chinese hamster lung fibroblasts. *J. Biol. Chem.* **258**: 3503–3508.
 72. L'ALLEMAIN, G., A. FRANCHI, E.J. CRAGOE, JR. & J. POUYSSÉGUR. 1984. Blockade of the Na^+/H^+ antiport abolishes growth factor-induced DNA synthesis in fibroblasts. Structure-activity relationships in the amiloride series. *J. Biol. Chem.* **259**: 4313–4319.
 73. GANAPATHY, V., D.F. BALKOVETZ, Y. MIYAMOTO, M.E. GANAPATHY, V.B. MAHESH, L.D. DEVOE & F.H. LEIBACH. 1986. Inhibition of human placental Na^+/H^+ exchanger by cimetidine. *J. Pharmacol. Exp. Ther.* **239**: 192–197.
 74. IVES, H.E., V.J. YEE & D.G. WARNOCK. 1983. Mixed type inhibition of the renal Na^+/H^+ antiporter by Li^+ and amiloride. Evidence for a modifier site. *J. Biol. Chem.* **258**: 9710–9716.
 75. WARNOCK, D.G., W.-C. YANG, Z.-Q. HUANG & E.J. CRAGOE, JR. 1988. Interactions of chloride and amiloride with the renal Na^+/H^+ antiporter. *J. Biol. Chem.* **263**: 7216–7221.
 76. FRANCHI, A., E.J. CRAGOE, JR. & J. POUYSSÉGUR. 1986. Isolation and properties of fibroblast mutants overexpressing an altered Na^+/H^+ antiporter. *J. Biol. Chem.* **261**: 14614–14620.
 77. COUNILLON, L., A. FRANCHI & J. POUYSSÉGUR. 1993. A point mutation of the Na^+/H^+ exchanger gene (NHE1) and amplification of the mutated allele confer amiloride resistance upon chronic acidosis. *Proc. Natl. Acad. Sci. USA* **90**: 4508–4512.
 78. COUNILLON, L., J. NOËL, R.A. REITHMEIER & J. POUYSSÉGUR. 1997. Random mutagenesis reveals a novel site involved in inhibitor interaction within the fourth transmembrane segment of the Na^+/H^+ exchanger-1. *Biochemistry* **36**: 2951–2959.
 79. WANG, D., D.F. BALKOVETZ & D.G. WARNOCK. 1995. Mutational analysis of transmembrane histidines in the amiloride-sensitive Na^+/H^+ exchanger. *Am. J. Physiol.* **269**: C392–C402.
 80. YUN, C.H.C., P.J. LITTLE, S.K. NATH, S.A. LEVINE, J. POUYSSÉGUR, C.M. TSE & M. DONOWITZ. 1993. Leu^{143} in the putative fourth membrane spanning domain is critical for amiloride inhibition of an epithelial Na^+/H^+ exchanger isoform (NHE-2). *Biochem. Biophys. Res. Commun.* **193**: 532–539.
 81. PETRECCA, K., R. ATANASIU, S. GIRINSTEIN, J. ORLOWSKI & A. SHRIER. 1999. Subcellular localization of the Na^+/H^+ exchanger NHE1 in rat myocardium. *Am. J. Physiol.* **276**: H709–H717.